Show All
When was Esperion founded and where is it incorporated?

Dr. Roger S. Newton, the co-discoverer and product champion for Lipitor, founded the second Esperion in 2008 after re-acquiring from Pfizer the name and program along with worldwide patent rights to bempedoic acid. The company was incorporated in the State of Delaware in 2008.

Esperion shares became available for public purchase in June 2013.

Shares of Esperion common stock are listed on the NASDAQ Global Market under the ticker symbol ESPR.

Esperion’s corporate headquarters are located in Ann Arbor, MI.

Computershare
462 South 4th St.
Ste 1600
Louisville, KY 40202
Phone: 877-373-6374

All notifications of change and/or inquiries regarding stock certificates should be sent to the transfer agent at:
Computershare
462 South 4th St.
Ste 1600
Louisville, KY 40202
Phone: 877-373-6374

Esperion does not offer a direct stock purchase plan. Shares of Company stock should be purchased through a broker.

Esperion's fiscal year is based on the calendar year. First quarter ends on March 31st. Second quarter ends June 30th. Third quarter ends September 30th. Fourth quarter ends December 31st.

Esperion does not currently pay a dividend.

Esperion’s auditors are Ernst and Young.

Please send inquiries by email to investorrelations@esperion.com, or contact Esperion IR by phone at 734-887-3903.

The Company will issue press releases from time to time to disclose information that is material, important, or of use to the public. Press releases may contain forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. Forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ significantly from those projected. The Company disclaims any obligation or undertaking to update any forward-looking statements contained in press releases, except as required by law. The press releases contained in this archive section are provided for convenience only. Press releases will be posted on Esperion’s Investors and Media section for thirty-six (36) months and, at that time, removed from the website. A copy of any archived press release can be requested by emailing investorrelations@esperion.com.

Bempedoic acid (ETC-1002) was discovered and patented by the original Esperion team. We re-acquired full worldwide rights to bempedoic acid from Pfizer in May 2008 when Pfizer announced they were exiting cardiovascular research and development. Bempedoic acid composition of matter (COM) patent coverage, including patent term extension (PTE), extends through 2030 in the U.S and through 2028 in Europe and Japan. Additionally, post-approval market exclusivity may also be available in certain territories. Patent coverage for bempedoic acid plus ezetimibe fixed-dose combination (BA + EZE FDC) is in prosecution worldwide.

Esperion is passionately committed to developing and commercializing complementary, oral therapies for patients and physicians globally that could potentially significantly reduce elevated levels of low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia inadequately treated with current lipid-modifying therapies.Bempedoic acid, Esperion-discovered and developed, brings a targeted mechanism of action to the space that could potentially address unmet medical needs.